$EVOK News
Last published 9mo ago
- 9mo agoEVOKApproval of Gimoti, Nda #209388 (Labeling)FDA Approved DrugsApproval Date: 02/09/2026; Drug Name: Gimoti, Nda #209388; Active Ingredients: METOCLOPRAMIDE HYDROCHLORIDE; Company: Evoke Pharma Inc; Submission Status: Approval; Submission Classification: Labeling; Application Number: 209388
- 10mo agoEVOKEvoke Pharma and QOL Medical Announce Expiration of Tender OfferPR NewswireEvoke Pharma, Inc. (formerly NASDAQ: EVOK) ("Evoke") and QOL Medical, LLC ("QOL Medical") today announced that the tender offer (the "Offer") by...
- 12mo agoEVOKEvoke Pharma Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireEntered into an Agreement to be acquired by QOL Medical Net product sales for the third quarter of 2025 reached $4.3 million; up 61% year-over-year Gimoti patent life for Gimoti extended through November 2038
- 1y agoEVOKEvoke Pharma Enters into Definitive Agreement to Be Acquired by QOL MedicalGlobeNewswireQOL Medical to Acquire All Outstanding Shares of Evoke for $11.00 Per Share in Cash Represents a 139.7% premium to most recent Nasdaq closing price Transaction expected to close by the end of 2025 SOLANA BEACH,
- 1y agoEVOKOMCLEvoke Pharma and EVERSANA Expand GIMOTI® Access to Gastro Health and Other Large GI Practices through Omnicell RelationshipGlobeNewswireSeparately Secures Access to OneGI Through Brentwood Pharmacy Agreement Gimoti Specialty Pharmacy Network to Almost Double with Additional Relationships SOLANA BEACH, Calif. and CHICAGO, Aug. 26, 2025 (GLOBE
- 1y agoEVOKEvoke Pharma Announces Listing of New GIMOTI® Patent in FDA Orange BookGlobeNewswireSOLANA BEACH, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on
- 1y agoEVOKEvoke Pharma Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireSOLANA BEACH, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI®
- 1y agoEVOKEvoke Pharma Announces Issuance of New U.S. Patent for GIMOTI With Extended Exclusivity to Late 2038GlobeNewswireSOLANA BEACH, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on
- 1y agoEVOKEvoke Pharma Reports First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireQ1 2025 Net Product Sales Increased 77% Year-over-Year to $3.1 Million Sustained Momentum Driven by Growing Prescriber Adoption and Repeat Patient Use SOLANA BEACH, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Evoke
- 1y agoEVOKEvoke Pharma to Present New Data Comparing Tardive Dyskinesia Incidence in Continuous vs Intermittent Metoclopramide Use at DDW 2025GlobeNewswireSOLANA BEACH, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI®,
- 1y agoEVOKEvoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateGlobeNewswireQ4 2024 revenue increased 24.6% over Q3 2024; Full-year 2024 revenue grew 97.8% year-over-year Strong growth in key commercial metrics, including prescriber base, fill rates, and patient enrollments Secured
- 1y agoEVOKEvoke Pharma to Report Fourth Quarter and Full Year 2024 Results on March 13, 2025GlobeNewswireSOLANA BEACH, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti®
- 1y agoEVOKEvoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of DirectorsGlobeNewswireSOLANA BEACH, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on
- 1y agoEVOKEvoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply EndsGlobeNewswireFDA posts update as mechanism to obtain unapproved Domperidone expected to lose supply in early 2025 Gimoti remains only approved drug shown to reduce hospitalizations, emergency room and medical office visits and
- 1y agoEVOKEvoke Pharma Receives Notices of Allowance for Two Additional US Patent Applications Protecting GIMOTI®GlobeNewswireSOLANA BEACH, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on
- 2y agoEVOKEvoke Pharma, Inc. Reports Third Quarter 2024 Financial ResultsGlobeNewswireGIMOTI third quarter net product sales of $2.7 million, highest quarterly revenue ever with a 70% increase year-over-year Strong cumulative prescriber growth, 45% year-over-year increase 52% year-over-year prescription
- 2y agoEVOKEvoke Pharma & EVERSANA Announce Statistically Significant Improvement in Patient Outcomes for GLP-1 users with Diabetic Gastroparesis using GIMOTI®GlobeNewswireAnalysis of real-world data compared patients on GIMOTI (n=51) to Oral Metoclopramide (n=41), both taking GLP-1s, showing significant statistical improvement for GIMOTI over Oral Metoclopramide in All Cause Emergency
- 2y agoEVOKEvoke Pharma to Showcase Award-Winning Research at the 2024 American College of Gastroenterology Annual Scientific MeetingGlobeNewswireSOLANA BEACH, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on
- 2y agoEVOKEvoke Pharma Announces the Appointment of Ben Smeal to the Board of DirectorsGlobeNewswireSOLANA BEACH, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on
- 2y agoEVOKEvoke Pharma Announces Proceeds from Existing Warrants and Board ExpansionGlobeNewswireNantahala to nominate 2 board seats Portion of the proceeds received from warrants executed at $8.16/share SOLANA BEACH, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a
- 2y agoEVOKEvoke Pharma Reaffirms Its Commitment to Patients with Gastroparesis Amid Industry DevelopmentsGlobeNewswireSOLANA BEACH, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on
- 2y agoEVOKEvoke Pharma to Participate in Gastroenterology and Hepatology Advanced Practice Providers (GHAPP) Annual ConferenceGlobeNewswireSOLANA BEACH, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on
- 2y agoEVOKEvoke Pharma to Present at H.C. Wainwright's 26th Annual Global Investment ConferenceGlobeNewswireSOLANA BEACH, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on
- 2y agoEVOKEvoke Pharma, Inc. Reports Second Quarter 2024 Financial ResultsGlobeNewswireGIMOTI second quarter net product sales grew 47% quarter-over-quarter and 126% year-over-year, indicating an annual run-rate in excess of $10 million Achieved record-high prescription fills during Q2 75%
- 2y agoEVOKEvoke Pharma, Inc. Supports Gastroparesis Awareness MonthGlobeNewswireCollaborating with advocacy groups to amplify gastroparesis awareness for millions of patients worldwide Call for action to improve health and access for patients SOLANA BEACH, Calif., Aug. 08, 2024 (GLOBE
- 2y agoEVOKEvoke Pharma, Inc. Announces Reverse Stock SplitGlobeNewswireSOLANA BEACH, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on
- 2y agoEVOKEvoke Pharma Reports Commercial Strategy Progress & Positive Momentum for GIMOTIGlobeNewswireExpanded State Medicaid Access for GIMOTI Achieved highest ever monthly GIMOTI prescription fills in May 2024 Promoted former VP of Finance, Mark Kowieski to Chief Financial Officer SOLANA BEACH, Calif., June
- 2y agoEVOKEvoke Pharma to Present Additional GIMOTI Healthcare Utilization Data Focused on Gastroparesis Care Insights in Women at 2024 Digestive Disease Week (DDW) ConferenceGlobeNewswireSOLANA BEACH, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on
- 2y agoEVOKEvoke Pharma Reports First Quarter 2024 Financial ResultsGlobeNewswire114% year-over-year increase in net product sales70% prescriber growth in Q1 2024 compared to Q4 2023Growing sales metrics reaffirms company's $14M net revenue guidance for 2024 SOLANA BEACH, Calif., May 14, 2024
- 2y agoEVOKEvoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 MedicationsGlobeNewswireSOLANA BEACH, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on
- 2y agoEVOKEvoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D'Onofrio to Chief Executive OfficerGlobeNewswireSOLANA BEACH, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on
- 2y agoEVOKEvoke Pharma, Inc. (EVOK) Q4 2023 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoEVOKEvoke Pharma Reports Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewswireFiscal year 2023 net product sales from prescriptions totaled approximately $5.2M, a 107% increase from 2022 Company projects $14M in net revenue for 2024 SOLANA BEACH, Calif., March 14, 2024 (GLOBE NEWSWIRE) --
- 2y agoEVOKEvoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024GlobeNewswireSOLANA BEACH, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti®
- 2y agoEVOKEvoke Pharma Announces Closing of $7.5 Million Public OfferingGlobeNewswireSOLANA BEACH, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on
- 2y agoEVOKEvoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 MillionGlobeNewswireSOLANA BEACH, Calif., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on
- 2y agoEVOKEvoke Pharma Announces FDA Orange Book Listing of New GIMOTI PatentGlobeNewswireSOLANA BEACH, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on
- 2y agoEVOKUnited States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTIGlobeNewswireSOLANA BEACH, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on
- 3y agoEVOKEvoke Pharma Reports Third Quarter 2023 Financial ResultsGlobeNewswire38% Revenue Increase Compared to Q2 2023; 88% Increase Year-Over-Year Seventh Straight Prescription Fill Increase Since Q1 2022 21% Increase Compared to Q2 2023; 95% Increase Year-Over-Year "Superiority of Nasal Spray
- 3y agoEVOKEvoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide Presented at the American College of Gastroenterology 2023GlobeNewswireSOLANA BEACH, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on
- 3y agoEVOKEvoke Pharma's Abstract Entitled "Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients" to Be Presented at The American College of Gastroenterology (ACG) 2023 Annual MeetingGlobeNewswireSOLANA BEACH, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on
- 3y agoEVOKEvoke Pharma Receives Notice of Allowance from USPTO for GIMOTI®GlobeNewswireSOLANA BEACH, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on
- 3y agoEVOKEvoke Pharma Reports Second Quarter 2023 Financial ResultsGlobeNewswire40% revenue growth compared to Q1 2023 34% increase in prescription fills compared to Q1 2023 Presented industry-leading real-world healthcare utilization data supporting the benefits of GIMOTI compared to oral
- 3y agoEVOKEvoke Pharma and EVERSANA Announce Abstract Acceptance at 2023 American Neurogastroenterology and Motility Society (ANMS) MeetingGlobeNewswireReal-world study that explored the healthcare utilization resource utilization among patients receiving GIMOTI with and without prior treatment with oral metoclopramide Both organizations recognize and support
- 3y agoEVOKEvoke Pharma and EVERSANA Announce Abstract Selection for Plenary Oral Presentation at The American College of Gastroenterology (ACG) 2023 Annual MeetingGlobeNewswireSOLANA BEACH, Calif., and CHICAGO, July 25, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an
- 3y agoEVOKEvoke Pharma to Host First Key Opinion Leader Webinar on Healthcare Resource Utilization Data Related to Gastroparesis and its TreatmentGlobeNewswireSOLANA BEACH, Calif., June 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on
- 3y agoEVOKEvoke Pharma Reports First Quarter 2023 Financial ResultsGlobeNewswireNet product sales increased by 94% from Q1 2022New cumulative prescribers up by 17% from Q4 2022Doubled patient enrollment since Q1 2022; 127% increase SOLANA BEACH, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Evoke
- 3y agoEVOKReal-World Data Presented by Evoke Pharma and EVERSANA at Digestive Disease Week 2023 Shows Gimoti® Meaningfully Reduces Utilization of Healthcare ResourcesGlobeNewswireSOLANA BEACH, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on
- 3y agoEVOKEvoke Pharma's Real-World Healthcare Utilization Data Comparing GIMOTI® to Oral Metoclopramide to Be Presented at Digestive Disease Week (DDW) 2023GlobeNewswireCompelling data elevated to distinguished DDW oral plenary session GIMOTI to be showcased in additional activities at conference SOLANA BEACH, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma,
- 3y agoEVOKNew GIMOTI Patent Listed in FDA Orange BookGlobeNewswireSOLANA BEACH, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on